Cargando…
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
BACKGROUND: In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12 years or older with mild-to-moderate COVID-19 who are at risk of progression to severe disease and hospitalisation. We aimed to establish the effectiveness of nirmatrelvir–ritonavir in preventing hospital a...
Autores principales: | Lewnard, Joseph A, McLaughlin, John M, Malden, Debbie, Hong, Vennis, Puzniak, Laura, Ackerson, Bradley K, Lewin, Bruno J, Kim, Jeniffer S, Shaw, Sally F, Takhar, Harpreet, Jodar, Luis, Tartof, Sara Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081864/ https://www.ncbi.nlm.nih.gov/pubmed/36933565 http://dx.doi.org/10.1016/S1473-3099(23)00118-4 |
Ejemplares similares
-
Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome
por: Lewnard, Joseph A., et al.
Publicado: (2023) -
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
por: Lewnard, Joseph A., et al.
Publicado: (2023) -
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
por: Tartof, Sara Y, et al.
Publicado: (2022) -
Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System
por: Tartof, Sara Y., et al.
Publicado: (2023) -
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
por: Tartof, Sara Y, et al.
Publicado: (2022)